Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance - PubMed (original) (raw)
Comparative Study
. 2004 Jan;164(1):217-27.
doi: 10.1016/S0002-9440(10)63112-4.
Priti Lal, Eva LaTulippe, Alex Smith, Jaya Satagopan, Liying Zhang, Charles Ryan, Steve Smith, Howard Scher, Peter Scardino, Victor Reuter, William L Gerald
Affiliations
- PMID: 14695335
- PMCID: PMC1602218
- DOI: 10.1016/S0002-9440(10)63112-4
Comparative Study
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
Jeff Holzbeierlein et al. Am J Pathol. 2004 Jan.
Abstract
The androgen-signaling pathway is critical to the development and progression of prostate cancer and androgen ablation is a mainstay of therapy for this disease. We performed a genome-wide expression analysis of human prostate cancer during androgen ablation therapy to identify genes regulated by androgen and genes differentially expressed after the development of resistance. Six hundred and fifty-four of 63,175 probe sets detected significant expression changes after 3 months of treatment with goserelin and flutamide. This included 149 genes that were also differentially expressed 36 hours after androgen withdrawal in LNCaP cells. These genes reflect the physiological changes that occur in treated tumors and include potential direct targets of the androgen receptor. Expression profiles of androgen ablation-resistant tumors demonstrated that many of the gene expression changes detected during therapy were no longer present suggesting a reactivation of the androgen response pathway in the absence of exogenous hormone. Therapy resistance was associated with differential expression of a unique set of genes that reflect potential mechanisms of reactivation. Specifically an up-regulation of the androgen receptor and key enzymes for steroid biosynthesis suggest that resistant tumors have increased sensitivity to and endogenous synthesis of androgenic hormones. The specific pathways of reactivation provide opportunities for classification of resistant tumors and targeted therapies.
Figures
Figure 1
Representative microscopic images of prostate cancers used for expression analysis. A: Typical histological appearance of hormone therapy naive (untreated) prostate cancer. B: Typical histological appearance of prostate cancer after 3 months of neoadjuvant androgen ablation therapy (treated).
Figure 2
Average linkage hierarchical clustering dendrograms of samples demonstrating relationship of gene expression profiles based on all 12,559 probe sets of U95A array. A: Untreated primary (green) and androgen ablation-treated primary prostate cancers (yellow). B: Untreated primary and androgen ablation-treated primary prostate cancers and androgen ablation-resistant metastatic prostate cancers (pink).
Figure 3
AR expression in human prostate cancers. A: Bar graph representing AR transcript levels based on hybridization of cDNA target to oligonucleotide arrays. Two different probe sets for AR are presented. B and C: Immunohistochemical detection of the AR in representative primary untreated prostate cancer with low level of AR transcripts (B) and metastatic AARPC with high levels (C). D and E: Fluorescent in situ hybridization for AR (red) and chromosome X centromere (green) in metastatic AARPC with high levels of AR transcripts and no amplification of the AR gene (D) and metastatic AARPC with high level of AR expression and AR amplification (E).
Figure 4
Schematic diagram of steroid biosynthesis with superimposed gene expression changes in androgen ablation-resistant prostate cancer.
Figure 5
Immunohistochemical detection of squalene monooxygenase in prostate cancer samples. Liver serves as positive control.
Similar articles
- Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM, Jenster G. Marques RB, et al. PLoS One. 2011;6(8):e23144. doi: 10.1371/journal.pone.0023144. Epub 2011 Aug 4. PLoS One. 2011. PMID: 21829708 Free PMC article. - Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M, Latham DE, Delaney MA, Chakravarti A. Zhang M, et al. Oncogene. 2005 Apr 7;24(15):2474-82. doi: 10.1038/sj.onc.1208490. Oncogene. 2005. PMID: 15735703 - Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
Ryan CJ, Smith A, Lal P, Satagopan J, Reuter V, Scardino P, Gerald W, Scher HI. Ryan CJ, et al. Urology. 2006 Oct;68(4):834-9. doi: 10.1016/j.urology.2006.04.016. Urology. 2006. PMID: 17070363 - Mechanisms leading to the development of hormone-resistant prostate cancer.
Kasper S, Cookson MS. Kasper S, et al. Urol Clin North Am. 2006 May;33(2):201-10, vii. doi: 10.1016/j.ucl.2005.12.010. Urol Clin North Am. 2006. PMID: 16631458 Review. - [Total androgen blockade].
Namiki M, Mizokami A. Namiki M, et al. Nihon Rinsho. 2002 Dec;60 Suppl 11:193-8. Nihon Rinsho. 2002. PMID: 12599570 Review. Japanese. No abstract available.
Cited by
- Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells.
Kirk JS, Wang J, Long M, Rosario S, Tracz A, Ji Y, Kumar R, Liu X, Jamroze A, Singh PK, Puzanov I, Chatta G, Cheng Q, Huang J, Wrana JL, Lovell J, Yu H, Liu S, Shen MM, Liu T, Tang DG. Kirk JS, et al. Cell Stem Cell. 2024 Aug 1;31(8):1203-1221.e7. doi: 10.1016/j.stem.2024.05.008. Epub 2024 Jun 14. Cell Stem Cell. 2024. PMID: 38878775 - CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer.
Azur RAG, Olarte KCV, Ybañez WS, Ocampo AMM, Bagamasbad PD. Azur RAG, et al. PLoS One. 2024 May 13;19(5):e0300413. doi: 10.1371/journal.pone.0300413. eCollection 2024. PLoS One. 2024. PMID: 38739593 Free PMC article. - Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression.
Pimenta R, Malulf FC, Romão P, Caetano GVB, da Silva KS, Ghazarian V, Dos Santos GA, Guimarães V, Silva IA, de Camargo JA, Recuero S, Melão BVLA, Antunes AA, Srougi M, Nahas W, Leite KRM, Reis ST. Pimenta R, et al. J Cancer Res Clin Oncol. 2024 Feb 2;150(2):70. doi: 10.1007/s00432-023-05598-x. J Cancer Res Clin Oncol. 2024. PMID: 38305916 Free PMC article. - Orexins and Prostate Cancer: State of the Art and Potential Experimental and Therapeutic Perspectives.
Costagliola A, Lombardi R, Liguori G, Morrione A, Giordano A. Costagliola A, et al. Cancer Genomics Proteomics. 2023 Dec;20(6suppl):637-645. doi: 10.21873/cgp.20412. Cancer Genomics Proteomics. 2023. PMID: 38035703 Free PMC article. Review. - Inhibition of N-myristoyltransferase activity promotes androgen receptor degradation in prostate cancer.
Alsaidan OA, Onobun E, Ye C, Lou L, Beharry Z, Xie ZR, Lebedyeva I, Crich D, Cai H. Alsaidan OA, et al. Prostate. 2024 Feb;84(3):254-268. doi: 10.1002/pros.24645. Epub 2023 Oct 31. Prostate. 2024. PMID: 37905842
References
- Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003: further decrease in mortality rate, increase in persons living with cancer. CA Cancer J Clin. 2003;53:5–26. - PubMed
- Barry M. Prostate specific antigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001;344:1373–1377. - PubMed
- Klocker H, Culig Z, Kaspar F, Hobisch A, Eberle J, Reissigl A, Bartsch G. Androgen signal transduction and prostatic carcinoma. World J Urol. 1994;12:99–103. - PubMed
- Logothetis CJ, Hoosein NM, Hsieh JT. The clinical and biological study of androgen independent prostate cancer (AI PCa). Semin Oncol. 1994;21:620–629. - PubMed
- Griffiths K, Morton MS, Nicholson RI. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Eur Urol. 1997;32:S24–S40. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical